2014
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515: 577-581. PMID: 25428507, PMCID: PMC4279952, DOI: 10.1038/nature13988.Peer-Reviewed Original Research
2006
Asynchronous Differentiation of CD8 T Cells That Recognize Dominant and Cryptic Antigens
Baron C, Meunier M, Caron É, Côté C, Cameron M, Kelvin D, LeBlanc R, Rineau V, Perreault C. Asynchronous Differentiation of CD8 T Cells That Recognize Dominant and Cryptic Antigens. The Journal Of Immunology 2006, 177: 8466-8475. PMID: 17142744, DOI: 10.4049/jimmunol.177.12.8466.Peer-Reviewed Original ResearchConceptsCD8 T cellsT cell responsesT cellsDay 10Cell responsesEffector CD8 T cellsEffector T cellsT cell differentiation markersT cell repertoireT cell differentiation programMouse AgCryptic antigensEffector potentialCell differentiation markersImmune responseCell repertoireEffector functionsAg specificityDay 15Differentiation programSelective expansionDifferentiation markersCell differentiation programLongitudinal analysisContraction phase